Chimerix (CMRX) to Release Quarterly Earnings on Thursday

Chimerix (NASDAQ:CMRX - Get Free Report) will likely be announcing its earnings results before the market opens on Thursday, March 6th. Analysts expect the company to announce earnings of ($0.26) per share and revenue of $0.31 million for the quarter.

Chimerix Price Performance

NASDAQ CMRX traded up $0.51 during trading hours on Friday, reaching $5.25. The company's stock had a trading volume of 1,921,602 shares, compared to its average volume of 1,664,568. The firm has a market capitalization of $472.16 million, a price-to-earnings ratio of -5.59 and a beta of 0.35. The company's 50-day moving average is $3.96 and its two-hundred day moving average is $2.10. Chimerix has a 1-year low of $0.75 and a 1-year high of $5.53.

Insider Activity at Chimerix

In other Chimerix news, CEO Michael T. Andriole sold 7,370 shares of the stock in a transaction dated Thursday, February 13th. The shares were sold at an average price of $4.52, for a total transaction of $33,312.40. Following the completion of the transaction, the chief executive officer now owns 609,603 shares of the company's stock, valued at $2,755,405.56. This trade represents a 1.19 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Over the last three months, insiders have sold 20,760 shares of company stock worth $91,175. Insiders own 13.10% of the company's stock.

Wall Street Analyst Weigh In

A number of equities research analysts have recently commented on the stock. HC Wainwright reiterated a "buy" rating and issued a $11.00 target price on shares of Chimerix in a research report on Tuesday, February 18th. Wedbush reiterated an "outperform" rating and issued a $7.00 price objective (up previously from $6.00) on shares of Chimerix in a report on Tuesday, February 18th.

Remove Ads

Chimerix Company Profile

Chimerix, Inc, a biopharmaceutical company, develops medicines to improve and extend the lives of patients facing deadly diseases. Its pipeline products include ONC201 a program that is in Phase 3 clinical trial for treating patients with H3 K27M-mutant diffuse glioma, as well as in Phase 2 clinical trial for the treatment of rare neuroendocrine tumors; and ONC206, an imipridone, Dopamine Receptor D2 (DRD2) antagonist, and caseinolytic protease P (ClpP) agonist, which is in Phase 1 clinical trial for adult and pediatric patients with primary central nervous system tumors.